Immunologic Factor
UCB’s Bimzelx Receives FDA Approval for Moderate-to-Severe Hidradenitis Suppurativa, Marking Fifth Indication
Bimzelx, Bimekizumab, Hidradenitis Suppurativa, FDA Approval, IL-17A and IL-17F Inhibitor, Chronic Inflammatory Skin Disease
FDA’s Peter Marks Advocates for Open Dialogue on Vaccines Amid Controversy
FDA, Peter Marks, Vaccines, Open Dialogue, RFK Jr, HHS Nomination
Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval
Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen
BeiGene Secures Long-Term Protection for BRUKINSA with Patent Settlement Until 2037
BeiGene, BRUKINSA, patent settlement, MSN Pharmaceuticals, generic competition, market exclusivity, BTK inhibitor, cancer treatment
Vaccine Stocks Plummet Globally Following RFK Jr.’s Nomination to Head HHS
RFK Jr., HHS appointment, vaccine stocks, pharmaceutical companies, stock market impact
EMA Reverses Decision, Recommends Approval of Lecanemab (Leqembi) for Early Alzheimer’s Disease in Specific Patient Group
Lecanemab, Leqembi, Alzheimer’s disease, EMA, CHMP, early Alzheimer’s disease, ApoE ε4, amyloid-beta monoclonal antibody
RFK Jr.’s HHS Nomination: A Potential Threat to the Biopharma Industry
RFK Jr., HHS nomination, biopharma industry, vaccine skepticism, health policies, Trump administration
Dupixent (Dupilumab) Advances Towards FDA Approval for Chronic Spontaneous Urticaria (CSU) in 2025
Dupixent, Dupilumab, Chronic Spontaneous Urticaria (CSU), FDA Review, Sanofi, Regeneron, Biologic Medicine, Type 2 Inflammation, H1 Antihistamines
Johnson & Johnson Expands Immunology Portfolio with $1.25B Acquisition of Yellow Jersey Therapeutics
Johnson & Johnson, Yellow Jersey Therapeutics, NM26, atopic dermatitis, bispecific antibody, immunology, Numab Therapeutics
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges